Autologous Bone Marrow Aspirate Concentrate
AssetAlso called BMAC
Autologous concentrated bone marrow cells delivering progenitor cells and anti-inflammatory factors for cartilage repair
- Stage
- Phase 3
- Modality
- Cell therapy
- Target
- Not known
- 2
- Indications
- 1
- Trial
- 1
- Developer
Trial NCT06216028 is still running. clinicaltrials.gov
Indications
2Knee osteoarthritis
Phase 3, Not yet recruiting, NCT06216028, clinicaltrials.gov, Oct 31, 2026
Musculoskeletal disease
Phase 3, Not yet recruiting, NCT06216028, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.